Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Nasdaq Composite falling over 50 points on Thursday. Shares of Ally Financial…
Tommy Tuberville Trades Raise Eyebrows Again: Senator Sells Put Options, Buys Small Biotech Linked To Ukraine-Russia War
Tommy Tuberville is one of the most active traders as a member of Congress. Here's a look at what he recently bought and sold.
Why Is Clinical-Stage Biotechnology Platform Company Humacyte Stock Gaining Friday?
Humacyte's shares surge as FDA grants Priority Review to its BLA for Human Acellular Vessel (HAV) used in urgent arterial repair.
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday.
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Redhill Biopharma (NASDAQ:RDHL) shares rose 11.1% to $0.99 during Tuesday’s after-market session. The market value of their…
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Exicure (NASDAQ:XCUR) shares increased by 50.0% to $0.93 during Tuesday’s after-market session. The market value of their…
10 Best Stock Traders In Congress In 2023 (Spoiler: Nancy Pelosi Is Back On The List)
A new report highlights the 10 members of Congress who profited the most from the stock market in 2023.
Tommy Tuberville Lost On Tesla Trade, Could Win Big On US Steel Trade: A Look At The Congress Trades Raising Eyebrows
Senator Tommy Tuberville has been actively trading United State Steel stock and options ahead of a proposed buyout.
Humacyte Submits Biologics License Application To U.S. FDA Seeking Approval Of Human Acellular Vessel For The Treatment Of Vascular Trauma
– BLA supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime trauma injuries in Ukraine – – The HAV had higher rates of
Humacyte Announces Two Presentations At The VEITHsymposium Of Clinical Results Of The Human Acellular Vessel In The Treatment Of Vascular Trauma
– Presentations included results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime injuries in Ukraine – – Results showed the HAV had higher